AU2740900A - Method of treating demyelinating inflammatory disease using ccr1 antagonists - Google Patents

Method of treating demyelinating inflammatory disease using ccr1 antagonists Download PDF

Info

Publication number
AU2740900A
AU2740900A AU27409/00A AU2740900A AU2740900A AU 2740900 A AU2740900 A AU 2740900A AU 27409/00 A AU27409/00 A AU 27409/00A AU 2740900 A AU2740900 A AU 2740900A AU 2740900 A AU2740900 A AU 2740900A
Authority
AU
Australia
Prior art keywords
ccr1
disease
antagonist
mice
function
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU27409/00A
Other languages
English (en)
Inventor
Wayne W. Hancock
James B. Rottman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Millennium Pharmaceuticals Inc
Original Assignee
LeukoSite Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by LeukoSite Inc filed Critical LeukoSite Inc
Publication of AU2740900A publication Critical patent/AU2740900A/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Immunology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU27409/00A 1999-01-29 2000-01-27 Method of treating demyelinating inflammatory disease using ccr1 antagonists Abandoned AU2740900A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24025399A 1999-01-29 1999-01-29
US09240253 1999-01-29
PCT/US2000/002124 WO2000044408A2 (fr) 1999-01-29 2000-01-27 Methode de traitement des troubles inflammatoires demyelinisants utilisant des agonistes de la fonction ccr1

Publications (1)

Publication Number Publication Date
AU2740900A true AU2740900A (en) 2000-08-18

Family

ID=22905789

Family Applications (1)

Application Number Title Priority Date Filing Date
AU27409/00A Abandoned AU2740900A (en) 1999-01-29 2000-01-27 Method of treating demyelinating inflammatory disease using ccr1 antagonists

Country Status (5)

Country Link
EP (1) EP1148889A2 (fr)
JP (1) JP2002535376A (fr)
AU (1) AU2740900A (fr)
CA (1) CA2361256A1 (fr)
WO (1) WO2000044408A2 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
UA77950C2 (en) 2000-10-04 2007-02-15 Applied Research Systems Use of mutants of cc chemokines for treatment of multiple sclerosis
AR038605A1 (es) 2002-02-25 2005-01-19 Elan Pharm Inc Uso de agentes para la manufactura de un medicamento para el tratamiento de inflamacion y composiciones para dicho tratamiento
AU2003240758B2 (en) 2002-04-04 2008-03-13 Laboratoires Serono Sa Chemokines mutants having improved oral bioavailability
US6727241B2 (en) * 2002-06-12 2004-04-27 Chemocentryx Anti-inflammatory compositions and methods of use
EP3527228A1 (fr) 2003-01-24 2019-08-21 Biogen MA Inc. Composition permettant de traiter des maladies dues à la démyélinisation et à la paralysie par administration d'agents de remyélinisation

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997024325A1 (fr) * 1995-12-28 1997-07-10 Takeda Chemical Industries, Ltd. DERIVES DE DIPHENYLMETHANE UTILISES COMME ANTAGONISTES DU RECEPTEUR MIP-1α/RANTES
JPH09249566A (ja) * 1996-03-19 1997-09-22 Takeda Chem Ind Ltd ピペリジン化合物含有ケモカイン受容体拮抗剤
JPH09249570A (ja) * 1996-03-19 1997-09-22 Takeda Chem Ind Ltd ベンゾジアゼピン化合物含有ケモカイン受容体拮抗剤
CN1248968A (zh) * 1997-02-26 2000-03-29 辉瑞大药厂 杂芳基－己酸酰胺衍生物、其制备方法及其作为MIP－1α与其CCRI受体结合的选择性抑制剂的用途
US6207665B1 (en) * 1997-06-12 2001-03-27 Schering Aktiengesellschaft Piperazine derivatives and their use as anti-inflammatory agents

Also Published As

Publication number Publication date
WO2000044408A3 (fr) 2000-12-14
WO2000044408A2 (fr) 2000-08-03
CA2361256A1 (fr) 2000-08-03
JP2002535376A (ja) 2002-10-22
EP1148889A2 (fr) 2001-10-31

Similar Documents

Publication Publication Date Title
CA2211578C (fr) Agent inhibitant la proteolyse des proteines musculaires contenant un anticorps dirige contre le recepteur de l'il-6
AU773293B2 (en) Anti-CCR4 antibodies and methods of use therefor
CA2201781C (fr) Traitement de la polyarthrite rhumatoide contenant un antagoniste de l'il-6 comme agent actif
US5888510A (en) Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
US8017121B2 (en) Chronic rheumatoid arthritis therapy containing IL-6 antagonist as effective component
US6245332B1 (en) Modulation of systemic memory T cell trafficking
Okamoto et al. Molecular targets of rheumatoid arthritis
WO2014003742A1 (fr) Agents anti-cxcl9, anti-cxcl10, anti-cxcl11, anti-cxcl13, anti-cxcr3 et anti-cxcr5 pour l'inhibition de l'inflammation
US20160130350A1 (en) Anti-cxcl9, anti-cxcl10, anti-cxcl11, anti-cxcl13, anti-cxcr3 and anti-cxcr5 agents for inhibition of inflammation
US20020055456A1 (en) Therapeutic methods that target fractalkine or CX3CR1
US20020042370A1 (en) Method of treating graft rejection using inhibitors of CCR2 function
US8795656B2 (en) Methods of treating rheumatoid arthritis by administering an anti-IL3 antibody
AU2740900A (en) Method of treating demyelinating inflammatory disease using ccr1 antagonists
WO1999025734A2 (fr) APPAUVRISSEMENT DE LA CELLULE Th2, COMPOSITIONS ET METHODES EN RAPPORT
Setoguchi et al. Combined effects of bucillamine and etanercept on a rat type II collagen-induced arthritis model
MXPA01007565A (en) Method of treating demyelinating inflammatory disease using ccr1 antagonists
AU732764B2 (en) Rheumatoid arthritis remedy containing IL-6 antagonist as effective component

Legal Events

Date Code Title Description
MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted